Showing results (181-190 of 248) with videos related to

Sort By:
Pageof 25
Cephalalgia : an International Journal of Headache|January 9, 2023
Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trialBrad C Klein, Rosa Miceli, Lawrence Severt, et al.
Annals of Neurology|April 13, 2000
Dopa-responsive dystonia due to a large deletion in the GTP cyclohydrolase I geneY Furukawa, M Guttman, S P Sparagana, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 7, 2009
Heavy holes as a precursor to superconductivity in antiferromagnetic CeIn3Suchitra E Sebastian, N Harrison, C D Batista, et al.
Ecology Letters|May 13, 2022
Future climate risks from stress, insects and fire across US forestsWilliam R L Anderegg, Oriana S Chegwidden, Grayson Badgley, et al.
Cephalalgia : an International Journal of Headache|December 9, 2024
Effect of preventive treatment with atogepant on quality of life, daily functioning, and headache impact across the spectrum of migraine: Findings from three double-blind, randomized, phase 3 trialsChristopher Gottschalk, Pranav Gandhi, Patricia Pozo-Rosich, et al.
The Lancet. Neurology|February 16, 2024
Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trialCristina Tassorelli, Krisztián Nagy, Patricia Pozo-Rosich, et al.
Headache|February 20, 2020
Ubrogepant, an Acute Treatment for Migraine, Improved Patient-Reported Functional Disability and Satisfaction in 2 Single-Attack Phase 3 Randomized Trials, ACHIEVE I and IIDavid W Dodick, Richard B Lipton, Jessica Ailani, et al.
Cephalalgia : an International Journal of Headache|November 26, 2020
Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implicationsPeter J Goadsby, Andrew M Blumenfeld, Richard B Lipton, et al.
Neurology|May 1, 1997
Oral phenylalanine loading in dopa-responsive dystonia: a possible diagnostic testK Hyland, J S Fryburg, W G Wilson, et al.
Cephalalgia : an International Journal of Headache|September 21, 2019
Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: Randomized, placebo-controlled trial in healthy adultsPeter J Goadsby, Stewart J Tepper, Paul B Watkins, et al.
Pageof 25